Trial Profile
A Phase 2b, Randomised, Double-Blind, Active Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients With Heart Failure and Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Balcinrenone (Primary) ; Dapagliflozin (Primary)
- Indications Heart failure; Renal failure
- Focus Therapeutic Use
- Acronyms MIRACLE
- Sponsors AstraZeneca
- 23 Oct 2023 Status changed from active, no longer recruiting to completed.
- 13 Oct 2023 This trial has been completed in Czech Republic (Global end date: 22 Sep 2023).
- 08 Oct 2023 This trial has been completed in Sweden (Global end date: 22 Sep 2023).